The lack of a marked treatment effect on DAS44-ESR, particularly during the post-dose follow-up period, may have been a consequence of changes in the background RA treatment regimen and/or the effect of decreasing acute phase proteins in the placebo group (baseline CRP was most pronounced in this group and therefore may have contributed to the high placebo response). Here, CRP is linked to rheumatoid arthritis.